esophageal cancer
Conditions
Interventions
Patients with HLA-A*2402 will undergo 2 set of weekly vaccination for 5 weeks followed by byweekly vaccinotion for 10 weeks in addition to standard therapy of 2 set of CDDP plus 5FU adjuvant chemother
Sponsors
Kinki University Faculty of Medicine
Human Genome Center, Institute of Medical Science, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with esophageal SCC who underwent currative (R0) resection without preoperative treatment and had pathological LN metastases 2)Laboratory values as follows Hemoglobin > 8.0g/dL 2000/mm3 < WBC < 15000mm3 Platelet count > 70000/mm3 Total bilirubin < 1.5mg/dL Asparate transaminase < 150U/L Alanine transaminase < 150U/L Serum creatinine < 3.0mg/dL PaO2 > 70mmHg 3)ECOG performance status 0-1 4)Age between 20 to 84 5)Male and female 6)Able and willing to give valid written informed consent
Exclusion criteria
Exclusion criteria: 1)Infectious disease (ex. patients with high fever of 38.5 degrees C or more, et cetra) 2)Severe heart disease or past history of the disease 3)Severe postoperative complications (ileus, interstitial pneumonia, uncontrolled DM, renal failure, cirrhosis, et cetra) 4)Severe mental disorder 5)Another active malignant disease 6)Brestfeeding and pregnancy (woman of child bearing potential) 7)Man with an intention to get with child 8)Autoimmune disease 9)Retention of pericardial fluid to cause heart failure or pericarditis 10)Decision of unsuitableness by principal investigator or physician-in-charge
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relapse free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease free survival Overall survival Adverse event Feasibility immunoresponse | — |
Countries
Japan
Contacts
Public ContactTakushi Yasuda
Kinki University Faculty of Medicine Department of Surgey
Outcome results
None listed